Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is actively advancing its innovative pipeline, which includes therapies targeting retinal diseases and mucosal vaccine platforms, contributing to an optimistic outlook on the company's potential. The company reported a significant increase in research and development expenses, indicating a strategic focus on expanding its capabilities and addressing unmet medical needs in retinal diseases, with FY25 R&D expenses reaching $39.8 million, up from $32.1 million in FY24. Additionally, encouraging results from ongoing clinical trials, including long-term efficacy data for its gene therapies, suggest the company may achieve meaningful improvements in vision function and patient outcomes in the future.

Bears say

Ocugen Inc. is facing multiple challenges that contribute to a negative outlook on its stock, particularly regarding the efficacy and safety of its therapeutic pipeline, which has struggled to meet clinical trial endpoints. The company’s focus on retinal diseases has not demonstrated the robust results needed to assure investors, highlighted by a mixed Phase 2 update that included only modest slowing of geographic atrophy lesions. Furthermore, the competitive landscape and reimbursement hurdles, as evidenced by the struggles faced by similar therapies, pose significant commercial risks that could limit Ocugen's market potential and impact financial performance.

Ocugen, Inc. (OCGN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.